Search Results - "MacBeth, Kyle J"

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype by Sallman, David A., McLemore, Amy F., Aldrich, Amy L., Komrokji, Rami S., McGraw, Kathy L., Dhawan, Abhishek, Geyer, Susan, Hou, Hsin-An, Eksioglu, Erika A., Sullivan, Amy, Warren, Sarah, MacBeth, Kyle J., Meggendorfer, Manja, Haferlach, Torsten, Boettcher, Steffen, Ebert, Benjamin L., Al Ali, Najla H., Lancet, Jeffrey E., Cleveland, John L., Padron, Eric, List, Alan F.

“…Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with…”
Get full text

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines by Hollenbach, Paul W, Nguyen, Aaron N, Brady, Helen, Williams, Michelle, Ning, Yuhong, Richard, Normand, Krushel, Leslie, Aukerman, Sharon L, Heise, Carla, MacBeth, Kyle J

“…The cytidine nucleoside analogs azacitidine (AZA) and decitabine (DAC) are used for the treatment of patients with myelodysplastic syndromes and acute myeloid…”
Get full text

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia by Wang, Feng, Morita, Kiyomi, DiNardo, Courtney D., Furudate, Ken, Tanaka, Tomoyuki, Yan, Yuanqing, Patel, Keyur P., MacBeth, Kyle J., Wu, Bin, Liu, Guowen, Frattini, Mark, Matthews, Jairo A., Little, Latasha D., Gumbs, Curtis, Song, Xingzhi, Zhang, Jianhua, Thompson, Erika J., Kadia, Tapan M., Garcia-Manero, Guillermo, Jabbour, Elias, Ravandi, Farhad, Bhalla, Kapil N., Konopleva, Marina, Kantarjian, Hagop M., Andrew Futreal, P., Takahashi, Koichi

“…Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in…”
Get full text

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia by GARCIA-MANERO, Guillermo, GORE, Steven D, KANTARJIAN, Hagop, SKIKNE, Barry, COGLE, Christopher, WARD, Renee, TAO SHI, MACBETH, Kyle J, LAILLE, Eric, GIORDANO, Heidi, SAKOIAN, Sarah, JABBOUR, Elias

“…To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of…”
Get full text

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies by Laille, Eric, Shi, Tao, Garcia-Manero, Guillermo, Cogle, Christopher R, Gore, Steven D, Hetzer, Joel, Kumar, Keshava, Skikne, Barry, MacBeth, Kyle J

“…CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this…”
Get full text

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) by Saft, Leonie, Karimi, Mohsen, Ghaderi, Mehran, Matolcsy, András, Mufti, Ghulam J, Kulasekararaj, Austin, Göhring, Gudrun, Giagounidis, Aristoteles, Selleslag, Dominik, Muus, Petra, Sanz, Guillermo, Mittelman, Moshe, Bowen, David, Porwit, Anna, Fu, Tommy, Backstrom, Jay, Fenaux, Pierre, MacBeth, Kyle J, Hellström-Lindberg, Eva

“…Del(5q) myelodysplastic syndromes defined by the International Prognostic Scoring System as low- or intermediate-1-risk (lower-risk) are considered to have an…”
Get full text

The JAMM motif of human deubiquitinase Poh1 is essential for cell viability by Gallery, Melissa, Blank, Jonathan L, Lin, Yinghui, Gutierrez, Juan A, Pulido, Jacqueline C, Rappoli, David, Badola, Sunita, Rolfe, Mark, Macbeth, Kyle J

“…Poh1 deubiquitinase activity is required for proteolytic processing of polyubiquitinated substrates by the 26S proteasome, linking deubiquitination to complete…”
Get full text

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS by Krönke, Jan, Fink, Emma C., Hollenbach, Paul W., MacBeth, Kyle J., Hurst, Slater N., Udeshi, Namrata D., Chamberlain, Philip P., Mani, D. R., Man, Hon Wah, Gandhi, Anita K., Svinkina, Tanya, Schneider, Rebekka K., McConkey, Marie, Järås, Marcus, Griffiths, Elizabeth, Wetzler, Meir, Bullinger, Lars, Cathers, Brian E., Carr, Steven A., Chopra, Rajesh, Ebert, Benjamin L.

“…Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). Here, we demonstrate that…”
Get full text

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib by Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Pollyea, Daniel A., Stone, Richard M., Altman, Jessica K., Roboz, Gail J., Patel, Manish R., Collins, Robert, Flinn, Ian W., Sekeres, Mikkael A., Stein, Anthony S., Kantarjian, Hagop M., Levine, Ross L., Vyas, Paresh, MacBeth, Kyle J., Tosolini, Alessandra, VanOostendorp, Jason, Xu, Qiang, Gupta, Ira, Lila, Thomas, Risueno, Alberto, Yen, Katharine E., Wu, Bin, Attar, Eyal C., Tallman, Martin S., de Botton, Stéphane

“…Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine…”
Get full text

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia by Pollyea, Daniel A., Tallman, Martin S., de Botton, Stéphane, Kantarjian, Hagop M., Collins, Robert, Stein, Anthony S., Frattini, Mark G., Xu, Qiang, Tosolini, Alessandra, See, Wendy L., MacBeth, Kyle J., Agresta, Samuel V., Attar, Eyal C., DiNardo, Courtney D., Stein, Eytan M.

“…Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12–15% of older…”
Get full text

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents by Santini, Valeria, Almeida, Antonio, Giagounidis, Aristoteles, Gröpper, Stefanie, Jonasova, Anna, Vey, Norbert, Mufti, Ghulam J, Buckstein, Rena, Mittelman, Moshe, Platzbecker, Uwe, Shpilberg, Ofer, Ram, Ron, Del Cañizo, Consuelo, Gattermann, Norbert, Ozawa, Keiya, Risueño, Alberto, MacBeth, Kyle J, Zhong, Jianhua, Séguy, Francis, Hoenekopp, Albert, Beach, C L, Fenaux, Pierre

“…This international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent…”
Get full text

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care by Döhner, Hartmut, Dolnik, Anna, Tang, Lin, Seymour, John F., Minden, Mark D., Stone, Richard M., del Castillo, Teresa Bernal, Al-Ali, Haifa Kathrin, Santini, Valeria, Vyas, Paresh, Beach, C. L., MacBeth, Kyle J., Skikne, Barry S., Songer, Steve, Tu, Nora, Bullinger, Lars, Dombret, Hervé

“…Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a…”
Get full text

Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome by Leung, Kevin K., Nguyen, Aaron, Shi, Tao, Tang, Lin, Ni, Xiaochun, Escoubet, Laure, MacBeth, Kyle J., DiMartino, Jorge, Wells, James A.

“…Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are diseases of abnormal hematopoietic differentiation with aberrant epigenetic alterations…”
Get full text

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer by Levy, Benjamin P., Giaccone, Giuseppe, Besse, Benjamin, Felip, Enriqueta, Garassino, Marina Chiara, Domine Gomez, Manuel, Garrido, Pilar, Piperdi, Bilal, Ponce-Aix, Santiago, Menezes, Daniel, MacBeth, Kyle J., Risueño, Alberto, Slepetis, Ruta, Wu, Xiaoling, Fandi, Abderrahim, Paz-Ares, Luis

“…Preclinical and early clinical studies suggest that combining epigenetic agents with checkpoint inhibitors can potentially improve outcomes in patients with…”
Get full text

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition by Harding, James J, Lowery, Maeve A, Shih, Alan H, Schvartzman, Juan M, Hou, Shengqi, Famulare, Christopher, Patel, Minal, Roshal, Mikhail, Do, Richard K, Zehir, Ahmet, You, Daoqi, Selcuklu, S Duygu, Viale, Agnes, Tallman, Martin S, Hyman, David M, Reznik, Ed, Finley, Lydia W S, Papaemmanuil, Elli, Tosolini, Alessandra, Frattini, Mark G, MacBeth, Kyle J, Liu, Guowen, Fan, Bin, Choe, Sung, Wu, Bin, Janjigian, Yelena Y, Mellinghoff, Ingo K, Diaz, Luis A, Levine, Ross L, Abou-Alfa, Ghassan K, Stein, Eytan M, Intlekofer, Andrew M

“…Somatic mutations in cytosolic or mitochondrial isoforms of isocitrate dehydrogenase ( or , respectively) contribute to oncogenesis via production of the…”
Get more information

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia by Cathelin, Severine, Sharon, David, Subedi, Amit, Cojocari, Dan, Phillips, Darren C., Leverson, Joel D., MacBeth, Kyle J., Nicolay, Brandon, Narayanaswamy, Rohini, Ronseaux, Sebastien, Liu, Guowen, Chan, Steven M.

Get full text

Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA by MacBeth, Kyle J., Chopra, Vivek S., Tang, Lin, Zheng, Bing, Avanzino, Brian, See, Wendy L., Schwickart, Martin, Figueroa, Maria E., Quek, Lynn, DiMartino, Jorge F.

“…•Enasidenib is an inhibitor of mutant IDH2 that releases the block in cellular differentiation imposed by aberrant production of 2-hydroxyglutarate.•Mechanisms…”
Get full text

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients by Santini, Valeria, Fenaux, Pierre, Giagounidis, Aristoteles, Platzbecker, Uwe, List, Alan F., Haferlach, Torsten, Zhong, Jim, Wu, Chengqing, Mavrommatis, Konstantinos, Beach, C. L., MacBeth, Kyle J., Almeida, Antonio

Get full text

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial by Stein, Eytan M, Fathi, Amir T, DiNardo, Courtney D, Pollyea, Daniel A, Roboz, Gail J, Collins, Robert, Sekeres, Mikkael A, Stone, Richard M, Attar, Eyal C, Frattini, Mark G, Tosolini, Alessandra, Xu, Qiang, See, Wendy L, MacBeth, Kyle J, de Botton, Stéphane, Tallman, Martin S, Kantarjian, Hagop M

“…Mutations in isocitrate dehydrogenase-2 (IDH2) occur in around 5% of patients with myelodysplastic syndromes. Neomorphic activity of mutant IDH2 proteins…”
Get full text

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes by Giagounidis, Aristoteles, Mufti, Ghulam J., Fenaux, Pierre, Germing, Ulrich, List, Alan, MacBeth, Kyle J.

“…Deletion of the long arm of chromosome 5, del(5q), is the most prevalent cytogenetic abnormality in patients with myelodysplastic syndromes (MDS). In…”
Get full text